ST elevation myocardial infarction. BA41
Conditions
Interventions
Intervention 1: Intervention group: curcumin capsule 500 mg. Intervention 2: Control group: placebo capsule 500mg.
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ST elevation myocardial infarction Successful treatment with percutaneous coronary intervention (PCI) on related vessel to infarct
Exclusion criteria
Exclusion criteria: Previous myocardial infarction lead to ejection fraction less than 50% malignant arrhythmia congenital heart disease cardiogenic shock history of suspicious or documented heart failure or decrease in left ventricular ejection fraction patients candidate for coronary artery bypass graft (CABG) or previous CABG patients with glomerular filtration rate lesser than 30 patients with history of autoimmune or connective tissue disorders patients with cancer pregnant or breastfeeding women patients with previous documented psychological disorders patients who can not complete their 2-month clinical followups during study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction. Timepoint: baseline and 60 days later. Method of measurement: By echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Major adverse cardiovascular events. Timepoint: during hospitalization and 60 days after starting study. Method of measurement: documents and reports of cardiac death, recurrent MI, culprit vessels revascularisation, cardiogenic shock, severe heart failure, major arrhythmia. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirhossein Sahebkar
Mashhad University of Medical Sciences
Outcome results
None listed